SPECIALIST COMMUNITY PUBLIC HEALTH NURSING

?
IBUPROFEN ALERT
INCREASED RISK OF SERIOUS CARDIOVASCULAR THROMBOTIC EVENTS, INCLUDING MYOCARDIAL INFARCTION, CVA, INCREASED RISK OF SEVERE GASTRO-INTESTINAL REACTIONS, INCLUDING ULCERATION, BLEEDING , PERFORATION
1 of 13
PHARMACOTHERAPEUTIC CLINICAL - NON STEROIDAL ANTI INFLAMMATORY DRUG
ANTIRHEUMATIC, ANALGESIC, ANTIPYRETIC, ANTIDYSMENORRHEAL, VASCULAR HEADACHE SUPPRESSANT
2 of 13
ACTION OF IBUPROFEN
INHIBITS PROSTAGLANDIN SYNTHESIS. PRODUCES VASODILATION ACTING ON HEAT-REGULATING CENTRE OF HYPOTHALAMUS. THERAPEUTIC EFFECT: PRODUCES ANALGESIC, ANTI-INFLAMMATORY EFFECTS; DECREASES FEVER
3 of 13
PHARMACOKINETICS OF IBUPROFEN
RAPIDLY ABSORBED FROM GASTRO INTESTINAL TRACT. PROTEIN BINDING: 90% - 99% METABOLISED IN THE LIVER. PRIMARILY EXCRETED IN THE URINE. NOT REMOVED BY HAEMODIALYSIS . HALF LIFE 2-4 HOURS
4 of 13
PRESCRIBING IBUPROFEN
IS THERE A NEED FOR THE DRUG , WOULD ANOTHER DRUG SUITE THE SITUATION, IS THE PERSON PREGNANT, WHAT THE PRESCRIPITON WOULD BE FOR EG PAIN, FEVER, REDUCE INFLAMMATION,
5 of 13
PRESCRIBING IBUPROFEN
ROUTH OF THE DRUG EG ORAL, DOSE AND FREQUENCY OF THE DRUG PRESCRIBED, HOW LONG PRESCRIBED FOR AND HOW TO MONITOR EFFECTS
6 of 13
PRESCRIBING IBUPROFEN
ADVICE AROUND TAKING FOOD WITH DRUG RE GASTRIC IRRITANT, WHETHER PATIENT HAS HAD A GASTRIC BLEED OR ULCERATION IN PAST HISTORY, WHETHER THEY HAVE CARDIO VASCUALAR CONDITIONS, OR IN THIRD TRIMESTER OF PREGNANCY CAN EFFECT FOETAL CARDIOVASCULAR SYSTEM
7 of 13
IBUPROFEN IN PREGNANCY
AVOID IN THIRD TRIMESTER ? WHETHER DRUG CROSES PLACENTAL BARRIER OR FOUND IN BREAST MILK. SAFETY OF DRUG NOT ESTABLISHED IN CHILDREN YOUNGER THAN 6 MONTHS
8 of 13
INDICATIONS TO IBUPROFEN
HISTORY OF HYPERSENSITIVITY TO ASPIRINS AND NSAIDs. CARDIOVASCULAR OPERATIONS,
9 of 13
ELDERLY AND IBUPROFEN
GASTRO INTESTINAL BLEEDING, ULCERATION MORE LIKELY TO CAUSE SERIOUS ADVERSE EFFECTS. AGE-RELATED RENAL IMPAIRMENT MAY INCREASE RISK OF HEPATIC / RENAL TOXICITY; REDUCED DOSAGE RECOMMENDED.
10 of 13
IBUPROFEN AND INTERACTIONS
MAY DECREASE EFFECTS OF ANTIHYPERTENSIVE DRUGS, DIURETICS, ASPIRIN, WITH INCREASED RISK OF GASTRO INTESTINAL EFFECTS, BLEEDING. MAY INCREASE EFFECTS OR WARFARIN AND RISK OF TOXICITY OF LITHIUM AND METHOTREXATE
11 of 13
IBUPROFEN ADMINISTRATION
ROUTES- ORAL, GEL, 200-400MG 4-6 HOURLY MAXIMUM DOSAGE 1,200 MG / DAILY / 6-8 HOURLY CHILDREN 6-11 YEARS 5-10MG MAXIMUM 40MG PER KG DAILY,
12 of 13
IBUPROFEN SIDE EFFECTS
OCCASIONAL - NAUSEA, VOMITING, DYSPEPSIA, DIZZINESS, RASH
13 of 13

Other cards in this set

Card 2

Front

PHARMACOTHERAPEUTIC CLINICAL - NON STEROIDAL ANTI INFLAMMATORY DRUG

Back

ANTIRHEUMATIC, ANALGESIC, ANTIPYRETIC, ANTIDYSMENORRHEAL, VASCULAR HEADACHE SUPPRESSANT

Card 3

Front

ACTION OF IBUPROFEN

Back

Preview of the front of card 3

Card 4

Front

PHARMACOKINETICS OF IBUPROFEN

Back

Preview of the front of card 4

Card 5

Front

PRESCRIBING IBUPROFEN

Back

Preview of the front of card 5
View more cards

Comments

No comments have yet been made

Similar Nursing resources:

See all Nursing resources »See all SCPHN resources »